OncLive® Events conducts independent live and virtual focus groups on a high-interest disease state with the goal to gain unbiased insights on the disease state, ongoing clinical trials, and market trends, including how specific drug candidates may fit into the treatment landscape. OncLive will independently recruit 8-12 academic or community advisors, and develop the full agenda and program content. Your team can silently observe these important discussions and will receive our executive summary post program.
Elisha Garcia
(609) 613-8698
egarcia@onclive.com
Chelsea DeLisa
(609) 529-9016
cdelisa@onclive.com
Name | Date | Location | Program Objective |
---|---|---|---|
OncLive® Metastatic NSCLC Workshop: Applying New Data to Patient Care | November | Virtual Program | View Program Objectives PDF |
The Evolving Role of Immunotherapy in Metastatic NSCLC | November/December | Virtual Program | View Program Objectives PDF |
Future Directions in Acute Myeloid Leukemia: An OncLive Scientific Workshop and Interchange | December | Virtual Program | View Program Objectives PDF |
OncLive® Scientific Interchange and Workshop: Advanced, HER2+ Expressing Breast Cancer | October | Virtual Program | View Program Objectives PDF |
Updates in Relapsed/Refractory Metastatic Renal Cell Carcinoma | October | Virtual Program | View Program Objectives PDF |
Current and Emerging Treatment for the Management of Tenosynovial Giant Cell Tumors | Ongoing Series | Virtual Program | View Program Objectives PDF |
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas | Ongoing Series | Virtual Program | View Program Objectives PDF |
Name | Date | Location | |
---|---|---|---|
ASCO GI: Current and Emerging Treatments For Neuroendocrine Tumors: An OncLive® Scientific Interchange and Workshop | January | San Francisco, CA | |
ASCO GI: HER2+ Gastrointestinal Malignancies: An OncLive Scientific Interchange and Workshop | January | San Francisco, CA | |
Advanced HER2 Expressing Breast Cancer Workshop | January | Miami, FL | |
Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma | February | Miami, FL | |
OncLive® Workshop Discussing Community-Based Management of Chronic Lymphocytic Leukemia (CLL) | February | Miami, FL | |
A Consultative Workshop on the Treatment of Hodgkin Lymphoma and Peripheral T-Cell Lymphoma | March | Kansas City, MO | |
Current and Emerging Concepts in Relapsed Refractory Diffuse Large B-cell Lymphoma | March | Virtual | |
Toxicity Management in Multiple Myeloma | March | Miami, FL | |
HER2+ Gastrointestinal Malignancies | March | Oxon, MD | |
Later Line Therapy for Advanced, HER2-Expressing Breast Cancer | March | Virtual | |
PARP Inhibition in Ovarian Cancer: Considerations for Maintenance Therapy: An OncLive Scientific Interchange and Workshop | March | Virtual | |
CSCC: Advancements in the Treatment of Keratinocyte Carcinomas | June | Virtual Program | View Program Objectives PDF |
ASCO: Non-Small Cell Lung Cancer Workshop | June | Virtual Program | Coming Soon |
PARP Inhibition in Ovarian Cancer: Considerations for Maintenance Therapy | June | Virtual Program | View Program Objectives PDF |
Advancements in the Treatment of Keratinocyte Carcinomas | June | Virtual Program | Coming Soon |
Antibody Drug Conjugates in HER2+ Breast Cancer | July | Virtual Program | View Program Objectives PDF |
BTK Inhibitors in B-Cell Malignancies OncLive Workshop | July 15 | Virtual Workshop | View Program Objectives PDF |
Current and Future Trends in NET | July 16 | Virtual Webcast | Coming Soon |
Current and Emerging Treatments in Follicular Lymphoma | July 29 | Virtual Workshop | View Program Objectives PDF |
The Role of Chemotherapy and Novel Combinations in Triple Negative Breast Cancer | July 29 | Virtual Program | View Program Objectives PDF |
Updates and New Targets in NSCLC | August 5 | Virtual Meeting | View Program Objectives PDF |
Updates in Metastatic Renal Cell Carcinoma: An OncLive Scientific Interchange and Workshop | August 6 | Virtual Meeting | View Program Objectives PDF |
Current and Emerging Treatments for the Management of Tenosynovial Giant Cell Tumors (TCGT) | August 12 | Virtual Webcast | View Program Objectives PDF |